Johnson & Johnson price target raised to $209 from $174 at Raymond James

Raymond James raised the firm’s price target on Johnson & Johnson to $209 from $174 and keeps an Outperform rating on the shares. Despite near-term pressure from Stelara’s loss of exclusivity, J&J remains optimistic, pointing to a strong pipeline and divestiture of slower-growth units as drivers of a new growth phase, the analyst tells investors in a research note. Management suggested 2026 consensus estimates may be too conservative, the firm says.